RenovoRx Statistics
Total Valuation
RenovoRx has a market cap or net worth of $24.95 million. The enterprise value is $13.20 million.
| Market Cap | 24.95M |
| Enterprise Value | 13.20M |
Important Dates
The next estimated earnings date is Tuesday, November 19, 2024, before market open.
| Earnings Date | Nov 19, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RenovoRx has 23.99 million shares outstanding. The number of shares has increased by 59.27% in one year.
| Current Share Class | 23.99M |
| Shares Outstanding | 23.99M |
| Shares Change (YoY) | +59.27% |
| Shares Change (QoQ) | +60.89% |
| Owned by Insiders (%) | 1.90% |
| Owned by Institutions (%) | 3.73% |
| Float | 23.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.16
| Current Ratio | 9.16 |
| Quick Ratio | 8.96 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -155.12% and return on invested capital (ROIC) is -122.73%.
| Return on Equity (ROE) | -155.12% |
| Return on Assets (ROA) | -70.08% |
| Return on Capital (ROIC) | -122.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.01M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.70% in the last 52 weeks. The beta is 0.99, so RenovoRx's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -8.70% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 1.22 |
| Relative Strength Index (RSI) | 55.48 |
| Average Volume (20 Days) | 18,605 |
Short Selling Information
The latest short interest is 91,861, so 0.38% of the outstanding shares have been sold short.
| Short Interest | 91,861 |
| Short Previous Month | 114,311 |
| Short % of Shares Out | 0.38% |
| Short % of Float | 0.39% |
| Short Ratio (days to cover) | 2.14 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.27M |
| Pretax Income | -8.05M |
| Net Income | -8.11M |
| EBITDA | n/a |
| EBIT | -10.27M |
| Earnings Per Share (EPS) | -$0.54 |
Balance Sheet
| Cash & Cash Equivalents | 11.74M |
| Total Debt | n/a |
| Net Cash | 11.74M |
| Net Cash Per Share | $0.49 |
| Equity (Book Value) | 9.27M |
| Book Value Per Share | 0.39 |
| Working Capital | 10.69M |
Cash Flow
| Operating Cash Flow | -9.28M |
| Capital Expenditures | n/a |
| Free Cash Flow | -9.28M |
| FCF Per Share | -$0.39 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RenovoRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -59.27% |
| Shareholder Yield | -59.27% |
| Earnings Yield | -32.52% |
| FCF Yield | -37.21% |
Analyst Forecast
The average price target for RenovoRx is $6.13, which is 489.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.13 |
| Price Target Difference | 489.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |